Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06PSS
|
|||
| Former ID |
DAP000918
|
|||
| Drug Name |
Nateglinide
|
|||
| Synonyms |
Fastic; IPCCPA; Senaglinide; Starlix; Starsis; Trazec; Nateglinide [INN]; Novartis brand of nateglinide; DJN 608; A-4166; AY-4166; DJN-608; Nate-glinide; Starlix (TN); YM-026; SDZ-DJN-608; N-((4-isopropylcyclohexyl)carbonyl)phenylalanine; Nateglinide, (D-Phe)-isomer; Nateglinide, (cis,D-Phe)-isomer; N-{[4-(propan-2-yl)cyclohexyl]carbonyl}phenylalanine; N-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanine; (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid; 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic complication [ICD-11: 5A2Y; ICD-9: 253.5, 588.1] | Approved | [1], [2] | |
| Therapeutic Class |
Hypoglycemic Agents
|
|||
| Company |
Norvatis Phamaceuticals Corporation
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H27NO3
|
|||
| Canonical SMILES |
CC(C)C1CCC(CC1)C(=O)NC(CC2=CC=CC=C2)C(=O)O
|
|||
| InChI |
1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15?,16?,17-/m1/s1
|
|||
| InChIKey |
OELFLUMRDSZNSF-OFLPRAFFSA-N
|
|||
| CAS Number |
CAS 105816-04-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
582898, 7848174, 7980094, 12013966, 14752539, 14874578, 26719880, 37101837, 39341005, 46386701, 46504836, 49681657, 49830241, 56313768, 57359430, 75919327, 81092826, 91748929, 92308370, 92308686, 92711649, 93166415, 103206766, 104253649, 114155796, 117890894, 124658899, 124757828, 124801358, 125164632, 126630653, 126657177, 128797137, 128797139, 128797141, 131293719, 131347903, 131860350, 135692483, 136949105, 137129256, 137175459, 137231395, 140330680, 142491149, 142619974, 143248460, 144204985, 151981031, 152100318
|
|||
| ChEBI ID |
CHEBI:31897
|
|||
| ADReCS Drug ID | BADD_D01539 | |||
| SuperDrug ATC ID |
A10BX03
|
|||
| SuperDrug CAS ID |
cas=105816044
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides eggerthii DSM20697
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nateglinide can be metabolized by Bacteroides eggerthii DSM20697 (log2FC = -0.385; p = 0.021). | |||
|
Studied Microbe: Bacteroides fragilis ATCC43859
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nateglinide can be metabolized by Bacteroides fragilis ATCC43859 (log2FC = -0.776; p = 0.003). | |||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nateglinide can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -0.756; p = 0.022). | |||
|
Studied Microbe: Bacteroides fragilis HMW 615
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nateglinide can be metabolized by Bacteroides fragilis HMW 615 (log2FC = -0.594; p = 0.03). | |||
|
Studied Microbe: Bacteroides fragilis str. 3986 T(B)9
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nateglinide can be metabolized by Bacteroides fragilis str. 3986 T(B)9 (log2FC = -0.551; p = 0.044). | |||
|
Studied Microbe: Bacteroides fragilis str. DS-208
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nateglinide can be metabolized by Bacteroides fragilis str. DS-208 (log2FC = -0.643; p = 0.016). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 3731
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nateglinide can be metabolized by Bacteroides thetaiotaomicron 3731 (log2FC = -0.42; p = 0.015). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 7330
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nateglinide can be metabolized by Bacteroides thetaiotaomicron 7330 (log2FC = -0.543; p = 0.01). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron VPI-5482
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nateglinide can be metabolized by Bacteroides thetaiotaomicron VPI-5482 (log2FC = -0.434; p = 0.009). | |||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nateglinide can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -0.706; p = 0.01). | |||
|
Studied Microbe: Bacteroides vulgatus ATCC 8482
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nateglinide can be metabolized by Bacteroides vulgatus ATCC 8482 (log2FC = -0.656; p = 0.05). | |||
|
Studied Microbe: Bacteroides xylanisolvens DSM18836
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nateglinide can be metabolized by Bacteroides xylanisolvens DSM18836 (log2FC = -0.536; p = 0.006). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nateglinide can be metabolized by Odoribacter splanchnicus (log2FC = -0.58; p = 0.008). | |||
|
Studied Microbe: Parabacteroides distasonis ATCC 8503
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nateglinide can be metabolized by Parabacteroides distasonis ATCC 8503 (log2FC = -0.487; p = 0.022). | |||
|
Studied Microbe: Parabacteroides merdae ATCC 43184
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nateglinide can be metabolized by Parabacteroides merdae ATCC 43184 (log2FC = -0.406; p = 0.003). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia hansenii DSM20583
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nateglinide can be metabolized by Blautia hansenii DSM20583 (log2FC = -0.489; p = 0.005). | |||
|
Studied Microbe: Clostridium sp.
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nateglinide can be metabolized by Clostridium sp. (log2FC = -0.354; p = 0.004). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Potassium channel unspecific (KC) | Target Info | Modulator | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6833). | |||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.